XML 110 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule Of Components Of (Loss) Income Before Income Tax
The components of (loss) income before income taxes for the following years ended December 31, are as follows: 
(Loss) Income Before Income Taxes:202320222021
Ireland$(45,689)$(53,717)$(36,631)
U.S.(114,942)(57,755)(56,687)
France(146)33 173 
Total loss before income taxes$(160,777)$(111,439)$(93,145)
Schedule Of Income Tax Provision (Benefit)
The income tax (benefit) provision consists of the following for the years ended December 31:  

 Income Tax (Benefit) Provision:202320222021
Current:  
U.S. - State$(661)$— $60 
Total current(661)— 60 
Deferred:  
U.S. - Federal— 25,896 (15,876)
U.S. - State160 129 — 
Total deferred160 26,025 (15,876)
Income tax (benefit) provision$(501)$26,025 $(15,816)
Schedule of Effective Income Tax Rate Reconciliation
The reconciliation between income taxes at the statutory rate and the Company’s (benefit) provision for income taxes is as follows for the following years ended December 31: 
 Reconciliation to Effective Income Tax Rate:202320222021
Income tax (benefit) provision - at statutory tax rate$(20,097)$(13,916)$(11,642)
Differences in international tax rates(6,341)(9,921)(8,950)
Change in valuation allowances24,332 48,734 4,296 
Nondeductible share-based compensation798 1,424 645 
Unrealized tax benefits160 258 239 
State and local taxes (net of federal)(5,614)(4,467)60 
Nondeductible interest expense4,362 4,239 2,173 
Orphan drug and R&D tax credit899 — (1,524)
Other1,000 (326)(1,113)
Income tax (benefit) provision - at effective income tax rate$(501)$26,025 $(15,816)
Summary of Unrecognized Tax Benefits
The following table summarizes the activity related to the Company’s unrecognized tax benefits for the twelve months ended December 31:

 Unrecognized Tax Benefit Activity202320222021
Balance at January 1: $3,143 $3,143 $3,143 
Increases for tax positions of prior years— — — 
Statute of limitations expiration(108)— — 
Settlements— — — 
Balance at December 31: $3,035 $3,143 $3,143 
Schedule of Deferred Tax Assets and Liabilities The net deferred tax assets (liabilities) at December 31, 2023 and 2022 resulted from the following temporary differences: 
 Net Deferred Tax Assets and Liabilities: 20232022
Deferred tax assets:  
Net operating loss carryforwards$71,051 $53,393 
Royalty income8,378 — 
Share-based compensation7,347 4,684 
Orphan drug and R&D tax credit4,065 4,964 
Capitalized research costs1,738 2,108 
Interest expense carryforward1,368 1,216 
Other1,322 1,521 
Amortization1,159 3,541 
Gross deferred tax assets96,428 71,427 
Deferred tax liabilities:  
Prepaid expenses— (86)
Gross deferred tax liabilities— (86)
Less: valuation allowances(96,428)(71,341)
Net deferred tax assets $— $—